MX2010007019A - Compuestos de bencimidazol. - Google Patents
Compuestos de bencimidazol.Info
- Publication number
- MX2010007019A MX2010007019A MX2010007019A MX2010007019A MX2010007019A MX 2010007019 A MX2010007019 A MX 2010007019A MX 2010007019 A MX2010007019 A MX 2010007019A MX 2010007019 A MX2010007019 A MX 2010007019A MX 2010007019 A MX2010007019 A MX 2010007019A
- Authority
- MX
- Mexico
- Prior art keywords
- benzimidazole compounds
- benzimidazole
- substituted
- lxrs
- receptors
- Prior art date
Links
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 title 1
- 102000004311 liver X receptors Human genes 0.000 abstract 2
- 108090000865 liver X receptors Proteins 0.000 abstract 2
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 abstract 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/10—Radicals substituted by halogen atoms or nitro radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere en general a moduladores basados en bencimidazol de receptores X del hígado (LXR) que tienen la fórmula (I) y a procedimientos relacionados: (ver fórmula (I)) en la que R2 es arilo C6-C10 o heteroarilo que incluye 5-10 átomos, cada uno de los cuales está: (i) sustituido con 1 R7, y (ii) opcionalmente sustituido con 1-5 Re; y R1, R3, R4, R5, R6 R7 y Re son como se definen en el presente documento.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1607007P | 2007-12-21 | 2007-12-21 | |
PCT/US2008/087735 WO2009086138A1 (en) | 2007-12-21 | 2008-12-19 | Benzimidazole compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2010007019A true MX2010007019A (es) | 2010-08-18 |
Family
ID=40386193
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2010007019A MX2010007019A (es) | 2007-12-21 | 2008-12-19 | Compuestos de bencimidazol. |
Country Status (9)
Country | Link |
---|---|
US (1) | US20110034526A1 (es) |
EP (1) | EP2231617A1 (es) |
JP (1) | JP2011507905A (es) |
CN (1) | CN101952257A (es) |
AU (1) | AU2008345696A1 (es) |
BR (1) | BRPI0821315A2 (es) |
CA (1) | CA2710461A1 (es) |
MX (1) | MX2010007019A (es) |
WO (1) | WO2009086138A1 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2820013T1 (sl) | 2012-03-02 | 2018-11-30 | Ralexar Therapeutics, Inc, | Modulatorji jetrnega x receptorja za zdravljenje dermalnih bolezni, motenj in stanj |
JP6320382B2 (ja) | 2012-08-13 | 2018-05-09 | ザ ロックフェラー ユニヴァーシティ | メラノーマの処置および診断 |
WO2015035027A1 (en) | 2013-09-04 | 2015-03-12 | Alexar Therapeutics, Inc. | Liver x receptor (lxr) modulators |
EP3626712A3 (en) | 2013-09-04 | 2020-04-15 | Ellora Therapeutics, Inc. | Liver x receptor (lxr) modulators |
EP2860177A3 (en) | 2013-09-20 | 2015-06-10 | Bayer Intellectual Property GmbH | Synthesis of functionalized arenes |
EP3091970B1 (en) | 2014-01-10 | 2020-10-28 | Rgenix, Inc. | Lxr agonists and uses thereof |
AU2017207291B2 (en) | 2016-01-11 | 2023-06-15 | The Rockefeller University | Methods for the treatment of myeloid derived suppressor cells related disorders |
CN106083729A (zh) * | 2016-07-01 | 2016-11-09 | 王建军 | 一种苯并咪唑类化合物的合成方法 |
JP2021504315A (ja) | 2017-11-21 | 2021-02-15 | ルジェニクス,インコーポレーテッド | 多形及びその使用 |
CN110372524B (zh) * | 2019-06-26 | 2022-08-30 | 天津理工大学 | 一种以联二萘胺为母核的三苯胺类有机空穴传输材料及其的合成及其用途 |
CN112341429B (zh) * | 2019-08-09 | 2021-11-23 | 成都先导药物开发股份有限公司 | 一种免疫调节剂的中间体化合物 |
US11174220B2 (en) | 2019-12-13 | 2021-11-16 | Inspirna, Inc. | Metal salts and uses thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2795730B1 (fr) * | 1999-07-01 | 2001-08-31 | Adir | Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US20040259948A1 (en) * | 2003-01-10 | 2004-12-23 | Peter Tontonoz | Reciprocal regulation of inflammation and lipid metabolism by liver X receptors |
US7245483B2 (en) * | 2003-07-18 | 2007-07-17 | Satori Labs, Inc. | Integrated personal information management system |
KR20070001922A (ko) * | 2003-12-12 | 2007-01-04 | 와이어쓰 | 심장혈관질환 치료에 유용한 퀴놀린 |
WO2007065864A1 (en) * | 2005-12-05 | 2007-06-14 | Neurosearch A/S | Benzimidazole derivatives and their use for modulating the gabaa receptor complex |
TWI391381B (zh) * | 2006-03-24 | 2013-04-01 | Neurosearch As | 新穎的苯并咪唑衍生物、含有其之醫藥組成物、及其於製造藥物之用途 |
US20080070883A1 (en) * | 2006-09-19 | 2008-03-20 | Wyeth | Use of LXR modulators for the prevention and treatment of skin aging |
-
2008
- 2008-12-19 US US12/809,873 patent/US20110034526A1/en not_active Abandoned
- 2008-12-19 CA CA2710461A patent/CA2710461A1/en not_active Abandoned
- 2008-12-19 CN CN2008801273634A patent/CN101952257A/zh active Pending
- 2008-12-19 AU AU2008345696A patent/AU2008345696A1/en not_active Abandoned
- 2008-12-19 EP EP08867575A patent/EP2231617A1/en not_active Withdrawn
- 2008-12-19 BR BRPI0821315A patent/BRPI0821315A2/pt not_active IP Right Cessation
- 2008-12-19 MX MX2010007019A patent/MX2010007019A/es not_active Application Discontinuation
- 2008-12-19 WO PCT/US2008/087735 patent/WO2009086138A1/en active Application Filing
- 2008-12-19 JP JP2010539886A patent/JP2011507905A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
WO2009086138A1 (en) | 2009-07-09 |
CN101952257A (zh) | 2011-01-19 |
AU2008345696A1 (en) | 2009-07-09 |
BRPI0821315A2 (pt) | 2019-09-24 |
CA2710461A1 (en) | 2009-07-09 |
JP2011507905A (ja) | 2011-03-10 |
EP2231617A1 (en) | 2010-09-29 |
US20110034526A1 (en) | 2011-02-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2010007019A (es) | Compuestos de bencimidazol. | |
BRPI0813271A2 (pt) | Síntese regiosseletiva catalisada por cobre de benzimidazóis e azabenzimidazóis | |
ATE542799T1 (de) | Chinolinonderivate als parp und tank-inhibitoren | |
MX2009007075A (es) | Metodos de uso para analogos de ciclopamina. | |
MX344330B (es) | Imidazoquinolinas substituidas novedosas. | |
JO2910B1 (en) | Organic compounds | |
SG163585A1 (en) | Melanocortin receptor ligands | |
MX2009011205A (es) | Derivados de 2-iminoisotiazol como ligandos del receptor canabinoide. | |
RS51970B (en) | TRICYCLIC UNITS AND THEIR USE AS MODULATORS OF GLUCOCORTICOID RECEPTORS | |
EA201170154A1 (ru) | Производные пиридинопиридинонов, способ их получения и применение в терапии | |
TW200942535A (en) | Novel compounds as cannabinoid receptor ligands | |
ATE541839T1 (de) | Pyrrolidiniumderivate als m3-muskarinische rezeptoren | |
DE602006014305D1 (de) | Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors | |
CY1112079T1 (el) | Νεες ενωσεις ως ανταγωνιστες των α1 υποδοχεων αδενοσινης | |
MX2009012374A (es) | Compuestos novedosos como ligandos del receptor de canabinoides. | |
ATE486058T1 (de) | Prolinamidderivate als nk3-antagonisten | |
EA201070321A1 (ru) | Замещённые пиперазинил-пиразины и пиридины в качестве антагонистов рецепторов 5-нт | |
EA200801549A1 (ru) | Новые производные фенантридина в качестве антагонистов брадикинина | |
MA32834B1 (fr) | 3-aminocyclopentanecarboxamides servant de modulateurs de recepteurs de chimiokines | |
ATE512142T1 (de) | Pyrimidin- und chinazolinderivate als modulatoren der somatostatin-rezeptor aktivität | |
TW200740766A (en) | Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6-ligands | |
NO20084698L (no) | Metode for fremstilling av indazolyl-ureaer som inhiberer vanilloidreseptor subtype 1(VR1) | |
EA200970189A1 (ru) | Пирролидинонанилины как модуляторы прогестероновых рецепторов | |
ATE546455T1 (de) | Spiropiperidinderivate als nk3-antagonisten | |
ATE549316T1 (de) | Piperidinderivate als nk3-rezeptorantagonisten |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |